Skip to main content
. 2018 Dec 20;11(1):3. doi: 10.3390/cancers11010003

Figure 4.

Figure 4

DUSP6 was regulated by pERK and not by p53. (A) Immunoblotting of A375 treated with nutlin-3 (5 µM) and RG7388 (1 µM) for 6 h. (B) Immunoblotting of WM35 treated with RG7388 (0.2 and 1 µM) for 6 h. (C) DUSP6 mRNA in A375 and WM35 treated with the indicated concentrations of nutlin-3 and RG7388 for 6 h, measured by qRT-PCR. (D,E) Immunoblotting of A375 (D) and WM35 (E) treated with trametinib for the indicated concentrations and times. (F) Changes of DUSP6 mRNA by qRT-PCR in WM35 treated with trametinib. (G) Immunoblotting of WM35 treated with trametinib (1 nM) and/or RG7388 (0.2 µM) for 6 and 24 h. TRA, trametinib.